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To assess the added value of the optic nerve region (by using visual evoked potentials [VEPs])
to the current diagnostic criteria.
Methods
From the Barcelona clinically isolated syndrome (CIS) cohort, patients with complete in-
formation to assess dissemination in space (DIS), the optic nerve region, and dissemination in
time at baseline (n = 388) were selected. Modified DIS (modDIS) criteria were constructed by
adding the optic nerve to the current DIS regions. The DIS andmodDIS criteria were evaluated
with univariable Cox proportional hazard regression analyses with the time to the second attack
as the outcome. A subset of these patients who had at least 10 years of follow-up or a second
attack occurring within 10 years (n = 151) were selected to assess the diagnostic performance.
The analyses were also performed according to CIS topography (optic neuritis vs non–optic
neuritis).
Results
The addition of the optic nerve as a fifth region improved the diagnostic performance by slightly
increasing the accuracy (2017 DIS 75.5%, modDIS 78.1%) and the sensitivity (2017DIS 79.2%,
modDIS 82.3%) without lowering the specificity (2017 DIS 52.4%, modDIS 52.4%). When the
analysis was conducted according to CIS topography, the modDIS criteria performed similarly
in both optic neuritis and non–optic neuritis CIS.
Conclusion
The addition of the optic nerve, assessed by VEP, as a fifth region in the current DIS criteria
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The improvement in diagnosis is one of the main advances
that have occurred in the multiple sclerosis (MS) field in the
past decades. Since 2001,1 dissemination in space (DIS) and
in time (DIT) can be established from MRI findings, and
since 2010, the diagnosis can be stablished shortly after pre-
senting a typical clinically isolated syndrome (CIS) on the
results of a single baseline MRI.2,3 More recently, oligoclonal
bands (OB) have been reincorporated into the 2017 di-
agnostic criteria as an alternative criterion for diagnosing MS
in the absence of DIT.3,4
Optic neuritis represents the first manifestation of MS in
25% to 35% of patients with CIS5,6 and will occur during
disease course in ≈70% of patients.5 The involvement of
the optic nerve can be established either clinically or by the
use of paraclinical tests such as visual evoked potentials
(VEPs), MRI, and optical coherence tomography (OCT).
In 2016, the Magnetic Resonance Imaging in Multiple
Sclerosis (MAGNIMS) group proposed the inclusion of
the optic nerve as an additional region to demonstrate
DIS.7 However, due to the lack of evidence regarding the
diagnostic properties of the different tests to assess the
optic nerve involvement in patients with CIS, the optic
nerve was finally not incorporated into the most recent
revision of the McDonald diagnostic criteria.3
A few studies have investigated the anterior visual pathway
involvement in CIS cohorts using clinical features,8
VEP,8,9 OCT,10–13 and MRI9,12,14 alone or in combination,
but only 2 of them have evaluated the diagnostic perfor-
mance of adding the optic nerve as a new region in the
diagnostic criteria,8,9 yielding somewhat contradictory
results. While the first study8 found that the addition of
optic nerve (evaluated mainly by clinical assessment)
would improve the diagnostic performance of 2017
McDonald criteria only in patients with optic neuritis CIS,
the study conducted by the MAGNIMS group9 concluded
that there was no clear improvement of the 2010 McDo-
nald criteria when the optic nerve region (assessed mainly
by VEP) was added to the 2010 DIS criteria. Moreover, the
modified DIS criterion that included the optic nerve was
the one with the lowest specificity.9
In this work, we have investigated the effect of adding the optic
nerve region (evaluated by VEP) as part of the DIS criteria to
improve the 2017 diagnostic criteria in a well-characterized
cohort of patients with CIS.6We have also compared the added
value of the fifth region according to optic nerve involvement
(symptomatic vs asymptomatic CIS).
Methods
Study Cohort
This observational, retrospective study was based on the
Barcelona CIS cohort. Clinical, demographic, biological, and
radiologic data are collected prospectively following a pre-
specified protocol described elsewhere.6,15 Briefly, patients
<50 years of age first seen within 3 months of symptom onset
were included. Demographic data, CIS topography, and
presence of OB at baseline were recorded, together with the
occurrence of a second attack during follow-up. Brain MRI
was obtained at baseline (within 5 months after CIS onset), at
1 year, and every 5 years thereafter. Beginning in 2007, spinal
cord MRIs were done at baseline as part of the diagnostic
process in all patients with CIS. MRI scans were obtained at
3.0T since 2010 and at 1.5T previously. Each MRI scan was
assessed by experienced neuroradiologists under normal
reporting conditions.
Pattern-reversal VEPs were performed during the diagnostic
process in the same location by an expert neurophysiologist
from the Neurophysiology Unit following international
guidelines.16 Although this is a prospective CIS cohort, the
date of VEP was not part of the initially collected information.
However, we have been able to retrieve this information from
electronic clinical records for 288 patients (74.2%). VEPs
were performed with a mean time from CIS to VEP of 3.95
months (SD 3.82 months). Preexisting eye conditions were
taken into account when VEP results were interpreted. Pa-
tients presenting with any ocular pathology that may affect
VEP were excluded. According to our normative data, VEPs
were considered abnormal if the latency of the P100 wave was
>112 milliseconds, there was an intereye latency asymmetry
>8, milliseconds, or there was an absence of the P100 wave.
Study Design
To evaluate the effect of adding new regions to fulfill DIS, we
performed a risk assessment analysis. We selected patients
with complete information to assess the 5 DIS regions (brain
and spinal cord MRI plus VEPs) and with gadolinium ad-
ministration at baseline to assess DIT (cohort 1). From this
cohort and to ensure that late converters were taken into
account, patients who had at least 10 years of follow-up or
who experienced a second attack within 10 years of the CIS
were selected to test the diagnostic criteria performance
(cohort 2) (figure). For both cohorts, DIS and DIT were
assessed at baseline. The modified DIS (modDIS) criteria
were constructed by adding the optic nerve region to the
current DIS topographies and using a cutoff value of 2 of 5.
The second attack was determined when new symptoms
Glossary
CI = confidence interval;CIS = clinically isolated syndrome;DIS = dissemination in space;DIT = dissemination in time;HR =
hazard ratio; MAGNIMS = Magnetic Resonance Imaging in Multiple Sclerosis; modDIS = modified DIS; MS = multiple
sclerosis; OB = oligoclonal bands; OCT = optical coherence tomography; VEP = visual evoked potential.
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suggestive of a relapse occurred during the follow-up after an
interval of at least 1 month since the CIS and in the absence of
fever or concurrent diseases.17
Statistical Analysis
Descriptive statistics were performed on the baseline vari-
ables. Normally distributed continuous variables were sum-
marized with means and SDs. Otherwise, continuous variables
were summarized with medians and ranges; categorical vari-
ables were summarized as percentages.
Cohort 1, Risk Assessment Analysis
For the risk assessment analysis, the number of DIS regions
fulfilled and the current and modDIS criteria were evaluated
with univariable Cox proportional hazard regression analyses
considering the time to the second attack during the follow-up
as the primary outcome and the time to 2017 McDonald MS
criteria fulfillment as the secondary outcome. The results are
expressed as the hazard ratios (HRs) with 95% confidence
intervals (CIs). The Schoenfeld residuals have been evaluated
to test the proportional risk assumption. Finally, because
initiating a disease-modifying treatment before a second at-
tack could have affected the primary outcome, a sensitivity
analysis with treatment exposure as a time-dependent variable
was also conducted.
Cohort 2, Diagnostic Criteria Performance
We analyzed the sensitivity, specificity, accuracy, positive
predictive value, and negative predictive value of the current
and modDIS criteria alone and in combination with either OB
or MRI DIT, with second attack and 2017 McDonald MS at
10 years as the primary and secondary outcomes, respectively.
A sensitivity analysis excluding patients with treatment onset
before presenting a second attack was conducted.
To test whether the fulfillment of the modDIS criteria would
have a different impact in symptomatic (optic neuritis) and
asymptomatic (non–optic neuritis) patients with CIS, both
risk assessment and diagnostic performance analyses were
conducted according to CIS topography.
All statistical tests were performed with SPSS software version
22 (SPSS Inc, Chicago, IL) and R version 3.6.0 (R Foundation
for Statistical Computing, Vienna, Austria).
Standard Protocol Approvals and
Patient Consents
This study received approval from the Clinical Research
Ethics Committee at Vall d’Hebron University Hospital. All
patients signed written informed consents.
Figure Patient Disposition
CIS = clinically isolated syndrome; MS = multiple
sclerosis; ON = optic neuritis.
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Data Availability
Anonymized data will be shared by request from any qualified
investigator.
Results
From January 1995 to December 2017, 1,337 patients were
included in the Barcelona CIS inception cohort; 99 patients
were excluded for different reasons (figure). Of the remaining
1,238 patients, 388 fulfilled the criteria for the risk assessment
analysis (cohort 1), and 151 were included in the diagnostic
criteria performance analysis (cohort 2). Baseline character-
istics of the whole cohort, cohort 1, and cohort 2 are detailed
in table 1. Of note, in the whole cohort (n = 1,238), patients
were younger, and there was a higher proportion of patients
with positive OB and with abnormal VEPs.
VEPs were abnormal in 126 of 388 patients (32.5%), being
asymptomatic in 13.6%. Mean time of follow-up was 62.7
months (SD 40.4 months) for cohort 1 and 88.9 months (SD
37.9 months) for cohort 2. Patients with the longest follow-up
(cohort 2) had a greater proportion of abnormal baselineMRI
and positive OB results. One hundred thirty patients (33.5%)
presented a second attack, and all occurred within the first 10
years after CIS onset (mean time 19.6 months, SD 22.3
months).
Risk Assessment Analysis (Cohort 1)
After presentation of a CIS, the risk of developing a second
attack during the follow-up increased as the number of regions
fulfilled at baseline increased (from HR 5.6, 95% CI 1.9–16.5
for 1 criterion to HR 22.7, 95% CI 7.9–65.7 for 5 criteria
affected) (table 2).
Both the 2017 DIS and modDIS criteria at baseline conferred a
similar risk for developing a second attack during follow-up
compared to patients not fulfilling these criteria (2017 DIS: HR
4.3, 95% CI 2.8–6.5; modDIS: HR 4.8, 95% CI 3.0–7.5) (table
2). Similar findings were obtained with the 2017 McDonald MS
as the outcome although with wider CIs (2017 DIS: HR 20.4,
95% CI 13.6–30.6; modDIS: HR 21.8, 95% CI 14.1–33.9).
In the sensitivity analysis including treatment exposure as a time-
dependent variable, similar results were found (HR 4.6, 95% CI
2.9–7.2 for 2017 DIS; HR 5.1, 95% CI 3.1–8.3 for modDIS).
When the risk assessment analysis was conducted according
to CIS topography, fulfilling either the 2017 DIS or modDIS
criteria (including the optic nerve region) conferred a similar
higher risk for developing a second attack during the follow-
up in patients with both optic neuritis and non–optic neuritis
CIS (table 3).
Diagnostic Criteria Performance Analysis
(Cohort 2)
The addition of the optic nerve region to the DIS criteria
improved the current DIS diagnostic performance by in-
creasing the accuracy and sensitivity without decreasing the
specificity (table 4). When the current and modDIS criteria
were considered along with the presence of OB or DIT, the
modified criteria remained more accurate and more sensitive
and had a specificity similar to that of the current 2017
McDonald MS criteria, although the improvement was less
Table 1 Baseline Characteristics
Whole Cohort (n = 1,238) Cohort 1 (n = 388) Cohort 2 (n = 151)
Age at CIS, mean (SD), y 31.6 (8.2) 33.5 (7.8) 32.4 (7.4)
Female, n (%) 842 (68.0) 263 (67.8) 108 (71.5)
CIS topography, n (%)
Optic neuritis 446 (36.0) 138 (35.6) 40 (26.5)
Non–optic neuritis 787 (63.6) 250 (64.4) 111 (73.5)
Positive OB, n (%) 582/990 (58.8) 182/335 (54.3) 100/136 (73.5)
Baseline EDSS score, median (range) 1.0 (0–5.5) 1.0 (0–4.5) 1.5 (0–4.5)
Abnormal MRI, n (%) 810 (71.2) 275 (71.1) 136 (90.1)
Gd-enhancing lesions, n (%) 235 (29.3) 114 (29.4) 71 (47.0)
Patients with abnormal VEPs, n (%) 415/1,098 (37.8) 126 (32.5) 53 (35.1)
Optic neuritis 297/416 (71.4) 92/138 (66.7) 28/40 (70.0)
Non–optic neuritis 118/682 (17.3) 34/250 (13.6) 25/111 (22.5)
Time of follow-up, mean (SD), mo 107.9 (98.0) 62.7 (40.4) 88.9 (37.9)
Abbreviations: CIS = clinically isolated syndrome; EDSS = Expanded Disability Status Scale; OB = oligoclonal bands; VEP = visual evoked potential.
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noticeable than when DIS was analyzed alone (table 4).
Similar results were obtained with 2017 McDonald MS as the
outcome (2017 DIS vs modDIS: sensitivity 80.7% vs 83.6%,
specificity 100% vs 100%, accuracy 82.1% vs 84.8%) and in the
sensitivity analysis including only patients who either were
never treated or started treatment after presenting a second
attack (data not shown).
When the diagnostic performance analysis was conducted
according to CIS topography, the addition of the optic nerve
region improved the current DIS diagnostic performance in
patients with both optic neuritis vs non–optic neuritis CIS,
although this improvement was more noticeable in symp-
tomatic (optic neuritis) patients (table 5). Again, when the
different DIS criteria were considered in combination with
presence of OB or DIT, adding the optic nerve region into the
DIS criteria also resulted in more accurate, more sensitive
diagnostic criteria, with a specificity similar to that of the 2017
McDonald MS criteria, although this improvement was less
noticeable (table 5).
Discussion
In patients presenting a CIS, the addition of the optic nerve
(both in symptomatic and asymptomatic patients) as a fifth
region to the current DIS criteria confers a higher risk for
developing a second attack during follow-up and slightly
improves the diagnostic criteria performance by increasing
sensitivity without losing specificity.
In our work, we have demonstrated that patients fulfilling the
modDIS criteria at baseline were at a high risk of developing a
second attack during follow-up, which was similar to the risk
observed in patients fulfilling the 2017 DIS criteria. These
findings are in line with the work by Filippi et al.9 that
Table 2 Risk Assessment Analysis for the Whole Cohort: HRs for Second Attack as the Outcome
No. (%) Second Attack, n (%) HR (95% CI)
No. of regions affected
1 criterion 78 (20.1) 19/78 (24.4) 5.6 (1.9–16.5)
2 criteria 49 (12.6) 21/49 (42.9) 11.7 (4.0–34.2)
3 criteria 71 (18.3) 38/71 (53.5) 15.8 (5.6–44.4)
4 criteria 57 (14.7) 24/57 (42.1) 12.5 (4.3–36.1)
5 criteria 39 (10.1) 24/39 (61.5) 22.7 (7.9–65.7)
2017 DIS vs modDIS
2017 DIS 205 (52.8) 103/205 (50.2) 4.3 (2.8–6.5)
modDIS 216 (55.7) 107/216 (49.5) 4.8 (3.0–7.5)
Abbreviations: CI = confidence interval; DIS = dissemination in space; HR = hazard ratio; modDIS = modified DIS.
The 2017 DIS criteria as defined in Thompson et al.3: at least 1 lesion in at least 2 of 4 areas of the CNS (periventricular, cortico-juxtacortical, infratentorial,
spinal cord). modDIS added optic nerve assessed by visual evoked potential: at least 1 lesion in at least 2 of 5 areas of the CNS (periventricular, cortico-
juxtacortical, infratentorial, spinal cord, optic nerve).
Table 3 Risk Assessment Analysis According to Optic Nerve Involvement: HRs for Second Attack as the Outcome
No. (%) Second Attack n (%) HR (95% CI)
Optic neuritis CIS (n = 138)
2017 DIS 61 (44.2) 23/61 (37.7) 3.8 (1.8–8.0)
modDIS 70 (50.7) 25/70 (35.7) 4.3 (1.9–9.6)
Non–optic neuritis CIS (n = 250)
2017 DIS 144 (57.6) 80/144 (55.6) 4.1 (2.4–6.9)
modDIS 146 (58.4) 82/146 (56.2) 4.6 (2.7–8.0)
Abbreviations: CI = confidence interval; CIS = clinically isolated syndrome; DIS = dissemination in space; HR = hazard ratio; modDIS = modified DIS.
The 2017 DIS criteria as defined in Thompson et al.3: at least 1 lesion in at least 2 of 4 areas of the CNS (periventricular, cortico-juxtacortical, infratentorial,
spinal cord). modDIS added optic nerve assessed by visual evoked potential: at least 1 lesion in at least 2 of 5 areas of the CNS (periventricular, cortico-
juxtacortical, infratentorial, spinal cord, optic nerve).
e486 Neurology | Volume 96, Number 4 | January 26, 2021 Neurology.org/N
evaluated the optic nerve involvement (mainly using VEPs) in
241 patients with CIS, reporting a similar higher risk for de-
veloping a second attack when patients fulfilled either the
2010 DIS criteria or the 2010 modDIS criteria including the
optic nerve (2010 DIS: 3.48, 95% CI 2.2–5.6; 2010 DIS plus
optic nerve: 3.34, 95% CI 1.9–5.6). In addition, we have
conducted the risk assessment analysis based on CIS topog-
raphy to test whether the fulfillment of the modDIS criteria
would have a different impact in symptomatic and asymp-
tomatic patients with CIS (optic neuritis vs non–optic neuritis
CIS) and found similar results. This probably means that
VEPs were able to capture optic nerve involvement in both
symptomatic and asymptomatic eyes18 and reinforces the fact
that symptomatic lesions should be taken into account when
considering the diagnosis of MS in patients with CIS.19,20
As for the diagnostic performance analysis, we have proved
that the addition of the optic nerve to the current DIS criteria
slightly increases the accuracy and sensitivity without low-
ering the specificity, both in the whole cohort and in
symptomatic and asymptomatic patients with CIS. These
results are partially discordant with the results published in 2
previous works showing that the addition of the optic nerve
to the DIS criteria increased the sensitivity at the expense of
decreasing the specificity.8,9 In the first work, Filippi et al.9
found that the addition of the optic nerve region to the 2010
DIS criteria increased the sensitivity by lowering the speci-
ficity of the 2010 criteria with second attack 5 years after
presenting the CIS used as the outcome (sensitivity: 2010
DIS 0.87 vs 2010 DIS + optic nerve 0.90; specificity: 2010
DIS 0.33 vs 2010 DIS + optic nerve 0.26).9 More recently,
Table 4 Diagnostic Performance Analysis: Diagnostic Properties at 10 years With Second Attack as the Outcome
% (95% CI)
Sensitivity Specificity Accuracy PPV NPV
2017 DIS 79.2 (71.2–85.8) 52.4 (29.8–74.3) 75.5 (67.8–82.1) 91.1 (86.7–94.2) 28.9 (19.4–40.9)
modDIS 82.3 (74.6–88.4) 52.4 (29.8–74.3) 78.1 (70.7–84.5) 91.4 (87.1–94.4) 32.3 (21.6–45.4)
2017 DIS + DIT and/or OB 73.9 (65.4–81.2) 66.7 (43.0–85.4) 72.9 (62.0–79.8) 93.2 (88.1–96.2) 29.2 (21.3–38.5)
modDIS + DIT and/or OB 74.2 (65.9–81.5) 66.7 (43.0–85.4) 73.2 (65.5–80.0) 93.2 (88.4–96.3) 29.2 (21.3–38.5)
Abbreviations: CI = confidence interval; DIS = dissemination in space; DIT = dissemination in time;modDIS =modifiedDIS; NPV = negative predictive value; OB
= oligoclonal bands; PPV = positive predictive value.
The 2017 DIS criteria as defined in Thompson et al.3: at least 1 lesion in at least 2 of 4 areas of the CNS (periventricular, cortico-juxtacortical, infratentorial,
spinal cord). modDIS added optic nerve assessed by visual evoked potential: at least 1 lesion in at least 2 of 5 areas of the CNS (periventricular, cortico-
juxtacortical, infratentorial, spinal cord, optic nerve).
Table 5 Diagnostic Performance Analysis According to Optic Nerve Involvement: Diagnostic Properties at 10 years With
Second Attack as the Outcome
% (95% CI)
Sensitivity Specificity Accuracy PPV NPV
Optic neuritis CIS (n = 40)
2017 DIS 69.7 (51.3–84.4) 57.1 (18.4–90.1) 67.5 (51.0–81.4) 88.5 (76.0–94.9) 28.6 (14.9–47.7)
modDIS 75.8 (57.7–89.0) 57.1 (18.4–90.1) 72.5 (56.1–85.4) 89.3 (77.6–95.2) 33.3 (17.2–54.7)
2017 DIS + DIT and/or OB 63.6 (45.1–79.6) 85.7 (42.1–99.6) 67.5 (50.9–81.4) 95.5 (77.1–99.2) 33.3 (22.5–46.3)
modDIS + DIT and/or OB 66.7 (48.2–82.0) 85.7 (42.1–99.6) 70.0 (53.5–83.4) 95.7 (77.9–99.3) 35.3 (23.6–49.1)
Non–optic neuritis CIS (n = 111)
2017 DIS 82.5 (73.4–89.5) 50.0 (23.0–77.0) 78.4 (69.6–85.6) 91.9 (87.0–95.1) 29.2 (17.3–44.8)
modDIS 84.5 (75.8–91.1) 50.0 (23.0–77.0) 80.2 (71.5–87.1) 92.1 (87.3–95.2) 31.8 (18.8–48.5)
2017 DIS + DIT and/or OB 77.3 (67.7–85.2) 57.1 (28.9–82.3) 74.8 (65.7–82.5) 92.6 (87.1–95.9) 26.7 (16.9-39-5)
modDIS + DIT and/or OB 78.4 (68.8–86.1) 57.1 (28.9–82.3) 75.7 (66.6–83.3) 92.7 (87.3–95.9) 27.6 (17.4–40.8)
Abbreviations: CI = confidence interval; CIS = clinically isolated syndrome; DIS = dissemination in space; DIT = dissemination in time; modDIS = modified DIS;
NPV = negative predictive value; OB = oligoclonal bands; PPV = positive predictive value.
The 2017 DIS criteria as defined in Thompson et al.3: at least 1 lesion in at least 2 of 4 areas of the CNS (periventricular, cortico-juxtacortical, infratentorial,
spinal cord). modDIS added optic nerve assessed by visual evoked potential: at least 1 lesion in at least 2 of 5 areas of the CNS (periventricular, cortico-
juxtacortical, infratentorial, spinal cord, optic nerve).
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Brownlee et al.8 analyzed the diagnostic performance of the
new modified criteria according to CIS topography (optic
neuritis and non–optic neuritis CIS) using the presence of a
second attack after a mean follow-up period of almost 15
years as the outcome. They reported that the inclusion of the
symptomatic optic nerve involvement (assessed mainly
clinically) increased the sensitivity and decreased the spec-
ificity of the 2017 DIS criteria (sensitivity: 2017 DIS 83% vs
2017 DIS + optic nerve 95%; specificity: 2017 DIS 68%,
2017 DIS + optic nerve 57%).8 Both works reported that the
decrease in specificity was no longer seen when the different
DIS criteria were evaluated along with DIT criteria. The
differences in the test specificity results between our work
and the previous published works may be explained in part
by the longer follow-up of our cohort compared with Filippi
et al., which may have allowed us to detect late converters, or
by the different methods used to evaluate optic nerve in-
volvement in the Brownlee et al. work. Moreover, we have
demonstrated that the addition of the optic nerve to the
2017 McDonald criteria increased the diagnostic perfor-
mance in patients with both optic neuritis (symptomatic)
and non–optic neuritis (asymptomatic) CIS, although to a
greater extent in the former group. These results are partially
discordant with the results published by Brownlee et al. and
may be partly explained by a slight overrepresentation of
optic neuritis in their work8 or by the fact that VEPs are more
capable of detecting subclinical optic nerve involvement
than clinical assessment alone.18,21–23
The 2016 MAGNIMS proposal suggested that optic nerve
involvement may be ascertained clinically (by detecting
optic nerve atrophy or pallor), with neurophysiologic tests
(VEPs), or by imaging with either MRI to detect optic
nerve lesions or OCT to detect peripapillary retinal
nerve fiber layer thinning.7 Assessment of optic nerve
involvement based only on clinical findings may be chal-
lenging if not assessed by a trained neuro-ophthalmolo-
gist,24 and thus, the use of paraclinical tests to confirm optic
nerve damage may be advisable. In addition, if we are trying
to increase the sensitivity of a diagnostic test, we may want
to use paraclinical tests that may allow us to detect a higher
proportion of patients with asymptomatic optic nerve in-
volvement compared to clinical tools alone. Full-field VEPs
have classically been used to provide paraclinical evidence
of demyelination to support the diagnosis of MS.17 Very
few studies have assessed VEPs in purely CIS cohorts,25–29
reporting rates of abnormal VEP results that range from
15% to 49% and that are in line with the abnormal VEP rate
of our study (32.5%). As expected, we have found VEPs to
be more frequently affected in patients with optic neuritis
CIS (66.7%), which is a result similar to that reported in the
literature (67.8%–87%).25,29 Most of the studies evaluating
VEPs in CIS cohorts were published before the imple-
mentation of the McDonald criteria25–27 to compare the
diagnostic properties of VEP and MRI to detect patients at
risk of developing MS during follow-up, concluding that
the MRI was the most sensitive tool.25–27 While the
diagnosis of MS has evolved tremendously since the use of
MRI, our work demonstrates the utility of VEPs (in com-
bination with brain and spinal cord MRI) in MS diagnosis,
supporting the reintroduction of this test in the diagnostic
workup of patients with CIS. It is important to bear in mind
that VEP results may be influenced by several factors
concerning test acquisition such as patient cooperation,
luminescence and contrast patterns, and stimuli pre-
sentation rate.30,31 To minimize these factors, VEPs should
be acquired following international guidelines,16 and a
normative dataset obtained from normal controls using
local equipment is commonly used to define the range of
normal variation.
Some limitations should be taken into consideration in the
interpretation of our results. VEPs were obtained as part of
the routine diagnostic process of patients with CIS, but in-
formation on the time elapsed since CIS to VEP was avail-
able for only three-quarters of the patients. Because patients
included in this analysis were slightly different from the full
Barcelona CIS cohort (n = 1,238), we cannot exclude some
minor selection bias. However, differences in VEP abnor-
malities were small (37.8 vs 32.5), and our results were still
significant even with a lower proportion of abnormal VEPs
in both cohorts 1 and 2. We also acknowledge that by
selecting only patients with complete information to analyze
the modDIS criteria (having brain and spinal cord MRI to-
gether with VEP information) and DIT criteria (adminis-
tration of gadolinium at baseline MRI), we could have
enriched our cohort. Last, we are aware that disease-
modifying treatment started before second attack could have
interfered with our results; however, no differences were
found in our sensitivity analysis when this information was
taken into account.
Since 2010, the McDonald diagnostic criteria have allowed
the diagnosis ofMS immediately after presentation of a typical
CIS,2,3 reducing patients’ uncertainty and improving earlier
treatment onset. However, with the exclusion of the optic
nerve as one of the relevant DIS regions, this early diagnosis
may not be applied to all patients equally because symp-
tomatic spinal cord and brainstem syndromes are more
meaningful in the diagnostic process than optic neuritis.32–34
Thus, in a patient presenting a brainstemCIS, the diagnosis of
MS can be established by showing 1 periventricular lesion and
1 enhancing brainstem lesion in brainMRI, while it will not be
the case if the same patient had presented an optic neuritis
with an abnormal VEP result and a brain MRI showing the
same enhancing periventricular lesion.
Our results show that the addition of the optic nerve, assessed
by VEP, as a fifth region in the current DIS criteria improves
the diagnostic performance by slightly increasing sensitivity
without losing specificity. Thus, our work provides additional
evidence that argues in favor of including the optic nerve as a
new region in the diagnostic criteria. Whether the optic nerve
involvement in patients with CIS should be confirmed only by
e488 Neurology | Volume 96, Number 4 | January 26, 2021 Neurology.org/N
means of VEPs, by the use of other structural tests (MRI or
OCT), or by a combination of them requires further in-
vestigation in prospective studies with a systematic examina-
tion of the optic nerve in patients with CIS.
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